Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZ-1101 vs Latanoprost in Glaucoma or Ocular Hypertension
NCT01896180Phase 2Completed
- Sponsor
- Alleanza Pharmaceuticals, Inc.
- Start
- Jul 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of latanoprost + dorzolamide in primary open-angle glaucoma (POAG) and ocular hypertension (2 arms), sponsored by Alleanza Pharmaceuticals, Inc. Primary endpoint: Mean Intraocular Pressure at 10 AM at 28 days. Started Jul 2013; status: completed.
02
Drugs
latanoprost + dorzolamide
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT01896180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01896180.